Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06812780 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT06812780 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 35 participants.
The verdict
NCT06812780, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.
Interventions
- DRUG AZD2389
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06812780
The ClinicalTrials.gov registry entry for NCT06812780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD2389 is the first listed.
NCT06812780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06812780 about?
NCT06812780 is a clinical study titled "A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389". The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.
What is the current status of trial NCT06812780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2025-02-04. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT06812780?
The interventions under investigation include: AZD2389 (DRUG).
Who is sponsoring clinical trial NCT06812780?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.